Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 537,700 shares, a decline of 5.4% from the December 31st total of 568,400 shares. Currently, 2.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 252,500 shares, the days-to-cover ratio is currently 2.1 days.

Institutional Trading of Carisma Therapeutics

Institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Carisma Therapeutics during the 2nd quarter worth about $40,000. Wexford Capital LP lifted its position in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Barclays PLC lifted its position in Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares in the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Stock Down 0.6 %

CARM opened at $0.46 on Tuesday. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market capitalization of $19.08 million, a price-to-earnings ratio of -0.29 and a beta of 1.56. The business has a 50-day moving average of $0.54 and a two-hundred day moving average of $0.84. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.77.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The company had revenue of $3.39 million during the quarter. On average, research analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Analysts Set New Price Targets

CARM has been the subject of several research reports. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. D. Boral Capital reissued a “buy” rating and issued a $12.00 target price on shares of Carisma Therapeutics in a research note on Monday, January 13th. Finally, Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the company from $10.00 to $1.00 in a research note on Thursday, December 12th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.94.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.